Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Insilico Medicine
If activity at the recent J.P. Morgan Healthcare Conference is an indication of what is up ahead, 2024 is set to be the year of big tech in biopharma.
Quantum computing is both mysterious and prone to hype, but the reality of a quantum era is approaching and the benefits for biopharma could be enormous. Prepare ahead of time to gain a first mover advantage, say the experts.
After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.
Private Company Edition: Fewer biotech companies raised venture capital in the second quarter, but the amount of capital raised was on par with the first quarter. Also, former BMS R&D exec Rupert Vessey joined Flagship Pioneering, two new VC funds emerged and Septerna raised a $150m series B round.
- Artificial Intelligence
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.